April 16, 2020 07:03 AM EDTUpdated April 17, 05:11 AM
Coronavirus

Covid-19 roundup: Blis­tered by heat­ed re­ac­tion to their role in the out­break, Bio­gen makes amends with Covid-19 'biobank’

Amber Tong

Senior Editor

Jason Mast

Editor

John Carroll

Editor & Founder

The Covid-19 out­break that Bio­gen ex­ecs un­wit­ting­ly fos­tered dur­ing their an­nu­al strat­e­gy meet­ing at the Boston Mar­riott Long Wharf in late Feb­ru­ary — dis­patch­ing in­fect­ed staffers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times